title: Novel treatments for castration-resistant prostate cancer.
abstract: The contemporary management of metastatic castration-resistant prostate cancer (mCRPC) is evolving dramatically. Understanding the biology of this disease, positive phase III studies and approvals for 4 novel agents in the US in 2010 and shortly in Europe have dramatically changed the therapeutic landscape.
authors.affiliation: Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy.
authors.forename: Cora N
authors.initials: CN
authors.lastname: Sternberg
mesh_terms: D002277:Carcinoma / Q000175:diagnosis / Q000601:surgery / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000601:surgery / Q000628:therapy*; D035703:Therapies, Investigational / Q000379:methods / Q000639:trends*; D017211:Treatment Failure
chemical_list: D015507:Drugs, Investigational